It’s likely related to McKinsey’s recommendations to Purdue that they attempt to get major pharmacies to “loosen up” on efforts to stop illegal opioid scripts (

It’s likely related to McKinsey’s recommendations to Purdue that they attempt to get major pharmacies to “loosen up” on efforts to stop illegal opioid scripts (which had resulted in an 18% reduction in OxyContin units sold by one major chain in particular). Paying kickbacks based on ODs would be a pretty blunt instrument that, I think, would have triggered alarm bells at those pharmacies’ leadership.